Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Mycobacterium ulcerans disease, a protocol for a randomised controlled trial in Ghana

BACKGROUND: Buruli ulcer (BU) can lead to disfiguring ulcers and permanent disability. The 2030 World Health Organization (WHO) road map for Neglected Tropical Diseases (NTDs) calls for major scaling up in diagnosis and management to eliminate disability due to the disease. Current treatment for BU...

Descripción completa

Detalles Bibliográficos
Autores principales: Amoako, Yaw Ampem, Agbanyo, Abigail, Novignon, Jacob, Owusu, Lucy, Tuffour, Joseph, Asante-Poku, Adwoa, Hailemichael, Yohannes, Mosweu, Iris, Canter, Ruth, Opondo, Charles, Allen, Elizabeth, Pitt, Catherine, Yeboah-Manu, Dorothy, Walker, Stephen L., Marks, Michael, Phillips, Richard Odame
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614217/
https://www.ncbi.nlm.nih.gov/pubmed/36825217
http://dx.doi.org/10.3310/nihropenres.13332.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614217/
https://www.ncbi.nlm.nih.gov/pubmed/36825217
http://dx.doi.org/10.3310/nihropenres.13332.2

Ejemplares similares